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Abstract
C7H7F3N2O2, monoclinic, P21/m (no. 11), a= 6.8088(8) Å,
b= 6.7699(9) Å, c= 9.9351(12) Å, β= 105.416(3)°,
V = 441.48(9) Å3, Z = 2, Rgt(F)=0.0398, wRref(F2)=0.1192,
T = 200(2) K.
CCDC no.: 2007110
The molecular structure is shown in the figure. Table 1
contains crystallographic data and Table 2 contains the list
of the atoms including atomic coordinates and displacement
parameters.
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Table 1: Data collection and handling.
Crystal: Colorless prism
Size: 0.32×0.19×0.08 mm
Wavelength: Mo Kα radiation (0.71073 Å)
µ: 0.16 mm−1
Diffractometer, scan mode: Bruker Apex-II, φ and ω
θmax, completeness: 33.2°, >99%
N(hkl)measured, N(hkl)unique, Rint: 17052, 1819, 0.025
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 1466
N(param)refined: 86
Programs: Bruker [1], SHELX [2, 3], Platon [4],
Mercury [5]
Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
F1 0.43896(17) 0.2500 0.08691(10) 0.0588(4)
F2 0.67754(12) 0.40673(15) 0.23115(9) 0.0573(3)
O1 0.85926(15) 0.2500 0.52269(12) 0.0416(3)
O2 0.70241(15) 0.2500 0.69374(10) 0.0336(2)
N1 0.16706(17) 0.2500 0.39173(13) 0.0314(3)
N2 0.23079(17) 0.2500 0.27439(13) 0.0319(3)
C3 0.43220(19) 0.2500 0.32107(13) 0.0263(2)
C4 0.49813(18) 0.2500 0.46784(13) 0.0235(2)
C5 0.31902(19) 0.2500 0.50850(14) 0.0272(3)
H5 0.3066 0.2500 0.6015 0.033*
C6 0.70491(19) 0.2500 0.56073(14) 0.0265(3)
C7 0.8989(2) 0.2500 0.79805(16) 0.0369(3)
H7A 0.9783 0.3688 0.7875 0.044*
C8 0.8546(3) 0.2500 0.93749(18) 0.0520(5)
H8A 0.9829 0.2500 1.0112 0.078*
H8B 0.7758 0.1318 0.9463 0.078*
C9 0.5551(2) 0.2500 0.21712(15) 0.0363(3)
H1N 0.041(3) 0.2500 0.387(2) 0.042(5)*
Source of material
The 4 cm3 of warm ethanolic solution of ethyl
3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (Sigma-
Aldrich) and 3 cm3 of warm ethanolic solution of
Zn(OAc)2 · 2H2O was mixed in ratio 1:2. The resulting unicolor
solution was allowed to concentrate at ambient conditions
for 3 days and the investigated sample material was filtered
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off and washed with ethanol. Colorless crystals of ethyl
3-(trifluoromethyl)-1H-pyrazole-4-carboxylate were obtained.
Experimental details
H atoms bonded to C atoms were placed at geometrically ide-
alized positions and refined as riding atoms [C—H=0.95–
0.99 Å and U iso(H)= 1.2Ueq(C) or 1.5Ueq(C)]. H atom attached
to N atom was located in difference Fourier maps and refined
isotropically.
Comment
Pyrazole derived compounds possess a wide range of bio-
logical activities including antimicrobial, antiviral, anti-
inflammatory, anticancer, analgesic, antipyretic [6–8];
accordingly, the pyrazole fragment represents an important
component of a number of therapeutic drugs [8 and refer-
ences therein]. The presence of fluoroalkyl substituents on
the pyrazole ring, as is the case with the pyrazole based
drug Celebrex, can improve the lipophilicity and solubil-
ity of a molecule and thus influence its biological activity
[9]. Also, the incorporation of carboxylic acid groups and
carboxylic ester functionality facilitates further modifica-
tion and improvement of bioactivity of the pyrazole based
molecules [10]. As a part of our continuous research interest
in the pyrazole derived compounds [11–13] we report here the
crystal structure of ethyl 3-(trifluoromethyl)-1H-pyrazole-4-
carboxylate.
In the title pyrazole derivative the pyrazole ring attaches
the fluoroalkyl and carboxylic ester substituents. The
molecule lies on a crystallographic mirror plane thus the
constituent atoms are coplanar, with the exception of F and
H atoms attached to sp3 carbon atoms (see the figure). Bond
lengths and angles are in the expected ranges [13–15]. In
the crystal the molecules interact by N1—H1· · ·O1ii hydrogen
bonds [H· · ·O 2.06(3) Å; N—H· · ·O 137(2)°; symmetry code:
(ii) x − 1, y, z] to form a chain along the crystallographic a
axis. The pyrazole hydrogen bonding acceptor N2 involves
only in a long contact with the terminal ester carbon, C8—
H8a· · ·N2ii [H· · ·N 2.71 Å; C—H· · ·O 158°; symmetry code:
(iii) x+ 1, +y, +z+ 1]. The planar molecules form the lay-
ered structure parallel to (010) plane. The mutual distance
between the neighboring layers is 3.385 Å [symmetry code
(i)= x, −y+ 1/2, z].
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